Track topics on Twitter Track topics that are important to you
CARLSBAD, CA -- (Marketwired) -- 07/23/15 -- True Diagnostics, Inc. ("True"), a leading global point-of-care company, announced today that it has received China CFDA clearance for its JIANJIE TSH Test and BOCHI Reader. The JIANJIE TSH test kit and BOCHI reader are powered by True's proprietary TrueDX Platform
The TrueDX Platform is a proprietary technology driving change within the diagnostic industry. With the TrueDX Platform, virtually any reference laboratory test method can be performed in any type of clinical setting. The TrueDX Platform has already proven capable of delivering increased stability and linearity over competing diagnostic platforms designed specifically for the laboratory.
Jerry Lee, President and CEO of True, stated, "This recent regulatory clearance brings us one step closer to providing medical professionals and patients access to accurate, faster and more cost-effective care. Through our strategic partnerships, we already have programs underway to help communities in need of thyroid disease monitoring. It's estimated that 98 million people in China suffer from thyroid disease and a significant portion require better access to affordable and precise diagnostic options for early identification and disease management."
About the Company
True Diagnostics, Inc. creates diagnostic solutions for the $18 billion point-of-care IVD market. After 30 years in the global medical diagnostic field, the inventor of the pregnancy test created the TrueDX Platform
, a patented platform which can measure the severity of any medical condition using only a finger prick of blood, small urine or saliva sample and more. The TrueDX Platform provides results in minutes (not days) and is portable. The TrueDX Platform takes point-of-care, point-of-incidence, and remote-of-care applications out of the lab to allow for immediate patient treatment. The flexibility of the TrueDX Platform creates unique and powerful opportunities for new diagnostic solutions through its ability to: 1) quickly bring new diagnostic tests to market; and 2) open new geographic and application-driven markets.
For more information, please visit www.TrueDiagnostics.comTrue Diagnostics, Inc. Jerry Lee President/CEO 760.683.9158 NEXT ARTICLE
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...